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Introduction: Both genetic variation in ATP-binding cassette sub-family G member 2 (ABCG2) and intake of
fructose-containing beverages are major risk factors for hyperuricemia and gout. This study aimed to test the
hypothesis that the ABCG2 gout risk allele 141 K promotes the hyperuricaemic response to fructose loading.
Methods: Healthy volunteers (n = 74) provided serum and urine samples immediately before and 30, 60, 120 and
180 minutes after ingesting a 64 g fructose solution. Data were analyzed based on the presence or absence of the
ABCG2 141 K gout risk allele.
Results: The 141 K risk allele was present in 23 participants (31%). Overall, serum urate (SU) concentrations during the
fructose load were similar in those with and without the 141 K allele (PSNP = 0.15). However, the 141 K allele was
associated with a smaller increase in SU following fructose intake (PSNP <0.0001). Those with the 141 K allele also had a
smaller increase in serum glucose following the fructose load (PSNP = 0.002). Higher fractional excretion of uric acid
(FEUA) at baseline and throughout the fructose load was observed in those with the 141 K risk allele (PSNP <0.0001).
However, the change in FEUA in response to fructose was not different in those with and without the 141 K risk allele
(PSNP = 0.39). The 141 K allele effects on serum urate and glucose were more pronounced in Polynesian participants
and in those with a body mass index ≥25 kg/m2.
Conclusions: In contrast to the predicted responses for a hyperuricemia/gout risk allele, the 141 K allele is associated
with smaller increases in SU and higher FEUA following a fructose load. The results suggest that ABCG2 interacts with
extra-renal metabolic pathways in a complex manner to regulate SU and gout risk.
Clinical Trials Registration: The study was registered by the Australian Clinical Trials Registry (ACTRN12610001036000).Introduction
Genetic variation in ATP-binding cassette sub-family G
member 2 (ABCG2) is a major risk factor for hyperurice-
mia and gout [1-3]. This gene encodes a high-capacity
urate exporter [2,3], expressed in the intestine, liver and
renal tubule [4]. The minor allele of rs2231142 (141 K),
that reduces efflux of uric acid by reducing expression of
ABCG2 [5], is strongly associated with increased risk of
hyperuricemia and gout [2,3,6,7]. Although ABCG2 is
thought to control efflux of uric acid from the renal
tubular cell into the lumen, a recent study has shown
that dysfunction of ABCG2 results in increased renal
uric acid excretion [8]. Furthermore, Abcg2-knockout* Correspondence: n.dalbeth@auckland.ac.nz
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reproduction in any medium, provided the ormice have increased serum urate concentrations, in-
creased renal uric acid excretion and reduced intestinal
uric acid excretion [8]. These findings have led to the con-
cept that ABCG2 expression in extra-renal tissues in-
fluences the effects of ABCG2 genetic variation on gout
risk, with the 141 K allele promoting extra-renal under-
excretion and increased urinary excretion of uric acid [8].
Ingestion of fructose is also strongly associated with
development of gout and hyperuricemia. In the Health
Professional Follow-up Study, the multivariate relative
risk for development of gout was 1.81 for those ingesting
the highest quintile of fructose (>11.8% energy/day) [9]
and each daily serving of sugar-sweetened beverage in-
creases the risk of prevalent gout by 13% [10]. Similarly,
in the National Health and Nutrition Examination
Survey (NHANES) III, the multivariate odds ratio forl Ltd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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quintile of fructose intake (>75 g/day), compared with
the lowest quintile of <10 g/day [11]. Intervention stu-
dies have shown that fructose ingestion can rapidly in-
crease serum urate concentrations [12-14]. This has
been attributed to hepatic metabolism of fructose, which
induces rapid depletion of ATP and increased urate pro-
duction by degradation of preformed purine nucleotides
[15]. It is possible that fructose also influences urate re-
lease from the hepatocyte into the systemic circulation
and renal excretion of uric acid [10,16]. Of particular
relevance to the current study is the observation that
fructose-induced hyperuricemia is accentuated in pa-
tients with gout and first-degree relatives of patients
with gout. In a small study of fructose-induced hyperuri-
cemia, increases in serum urate were significantly higher
in children of those with gout compared with healthy
controls without a family history of gout [12], suggesting
that fructose-induced hyperuricemia has a genetic com-
ponent. We have recently reported that variation in
the other major genetic risk factor for gout, solute car-
rier family 2, facilitated glucose transporter member 9
(SLC2A9), influences serum urate and fractional excre-
tion of uric acid (FEUA) responses to a fructose load
[17]. As ABCG2 and SLC2A9 are the two major genetic
risk factors for gout [7], we wished to examine whether
variation in ABCG2 also contributes to serum urate re-
sponses to a fructose load. The aim of this study was to
test the hypothesis that the ABCG2 gout risk allele
141 K also promotes the serum urate response to fruc-
tose loading.
Methods
This acute intervention study was designed to examine
the influence of genetic variants on acute fructose-
induced hyperuricemia in healthy participants. The me-
thods of this study have been previously reported in
detail [17]. Analysis of ABCG2 was prespecified. Exclu-
sion criteria were: gout, diabetes mellitus or fructose in-
tolerance, diuretic use, fasting glucose >6 mmol/L. The
study was approved by the New Zealand Multiregional
Ethics Committee, and each participant gave written in-
formed consent.
Following an overnight fast, participants consumed a
sugar solution between 8 am and 9 am, and blood was ob-
tained prior to ingestion and then 30 minutes, 60 minutes,
120 minutes, and 180 minutes after ingestion. Urine was
obtained at each time point for testing of urate and cre-
atinine. Weight and height were measured at the start of
the study visit, and body mass index (BMI) was calculated.
The sugar solution of 300 kcal/300 ml was consumed
within 10 minutes, according to the protocol of Akhaven
and Anderson for fructose-induced hyperuricemia [13].
This solution contained 80% fructose and 20% glucose(64 g fructose and 16 g glucose). Higher proportions of
fructose, even at low concentrations, are poorly tolerated
due to side effects of nausea and diarrhoea. The addition
of glucose reduces these side effects [13].
Serum and urine chemistry was measured using the
Roche Cobas c702 analyzer (Roche Diagnostics, Basel,
Switzerland). L-Lactate and fructose concentrations in the
60-minute serum samples were measured using fluores-
cence-based assays (both Cayman Chemical Company,
Ann Arbor, MI, USA) according to the manufacturer’s
instructions. This time point was chosen as both serum
lactate and fructose concentrations peak 60 minutes after
intake of an oral fructose load [16]. Genotyping of the
single nucleotide polymorphism (SNP) rs2231142 was
done using TaqMan SNP genotyping assay technology
(Applied Biosystems, Carlsbad, CA) [6]. Genotyping was
performed on 20 ng of genomic DNA using predesigned
TaqMan® SNP drug metabolism assays (Life Technologies,
Carlsbad, CA, USA) at 10× probe concentration, with
ABsolute QPCR Rox Mix (Thermo Fisher Scientific,
Waltham, M, USA) in a final reaction volume of 5 uL. The
primer and probe sequences remain the proprietary infor-
mation of Life Technologies. However, the context sequence
for rs2231142 (assay ID C__15854163_70) is (VIC/FAM)
GCAAGCCGAAGAGCTGCTGAGAACT(G/T)TAAGTT
TTCTCTCACCGTCAGAGTG. PCR was undertaken fol-
lowing the instructions of Thermo Fisher Scientific, specif-
ically one enzyme activation cycle (95°C, 15 minutes)
followed by 40 cycles of denaturation (95°C, 15 seconds)
and annealing/extension (60°C, 1 minute). Assays were run
on a Lightcycler® 480 Real-Time Polymerase Chain Reac-
tion System (Roche, Indianapolis, IN, USA), and analyzed
using the Lightcycler® 480 software. Successful genotyping
data were available for 74 participants: 25 European
Caucasian, 23 Eastern Polynesian (New Zealand Māori and
Cook Island Māori) and 26 Western Polynesian (Samoan,
Tongan, and Niuean) participants, and are included in the
analysis. The Q126X SNP rs72552713 was also genotyped
using the Taqman assay as described above (the context se-
quence for rs72552713 (assay ID C__98388180_20) is [VIC/
FAM] AATGCAAACCCACTAATACTTACTT[G/A]TAC
CACGTAACCTGAATTACATTTG). All participants were
homozygous for the major G allele. Therefore, no further
analysis is presented for this variant.
The analysis plan specified change in serum urate as
the primary endpoint. The key secondary endpoint was
change in fractional excretion of uric acid (FEUA; the ra-
tio between the renal clearance of uric acid to the renal
clearance of creatinine, expressed as a percentage). Sam-
ple size calculations were based on the previous study of
fructose-induced hyperuricemia by Stirpe et al. [12] This
study showed significant differences between healthy
volunteers with and without a family history of gout
with 5 to 6 participants per group (all of European
Table 1 Participant characteristics at baseline
Risk allele present, n = 23 Risk allele absent, n = 51 P
Age, years 26.8 (13.6) 32.9 (16.5) 0.13
Male sex, n (%) 18 (78%) 25 (49%) 0.023
Body mass index, kg/m2 26.9 (4.9) 27.8 (6.0) 0.56
Waist circumference, cm 93.0 (11.7) 92.7 (17.9) 0.94
Systolic blood pressure, mmHg 127 (14) 127 (18) 0.99
Diastolic blood pressure, mmHg 70 (8) 72 (10) 0.44
Serum urate 0.41 (0.12) mmol/L 0.34 (0.1) mmol/L 0.018
(6.8 (2.0) mg/dL) (5.7 (1.7) mg/dL)
Serum urate, adjusted for sex 0.37 (0.09) mmol/L 0.34 (0.09) mmol/L 0.21
(6.2 (1.5) mg/dL) (5.7 (1.5) mg/dL)
Serum creatinine, mmol/L 0.084 (0.013) 0.077 (0.016) 0.088
Fractional excretion of uric acid, % 6.25 (2.86) 5.62 (1.78) 0.26
Fractional excretion of uric acid, % adjusted for sex 6.61 (2.06) 5.4 (2.07) 0.031
Serum glucose, mmol/L 4.69 (0.38) 4.69 (0.45) 0.99
Māori or Pacific ancestry, n (%) 16 (70%) 33 (65%) 0.79
Eastern Polynesian, n (%) 4 (17%) 19 (37%) 0.11
Western Polynesian, n (%) 12 (52%) 14 (27%) 0.064
European ancestry, n (%) 7 (30%) 18 (35%) 0.79
Unless specified, data are presented as mean (SD).
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lele for analysis, and assumed that approximately 30% of
participants would have the gout risk allele, based on
our previous work [6]. In the smallest group compari-
son, n = 7 versus n = 18 within an ancestral subgroup,
there was in excess of 90% power (at the 5% significance
level for a two-tailed test) to detect a difference in the
change in serum urate 120 minutes after an oral fructose
challenge of at least the magnitude seen in the study byFigure 1 Effect of ABCG2 genotype on serum urate concentrations du
concentration. (B) Change in serum urate concentration. Data are presente
shown throughout.Stirpe et al. [12]. Sample size calculations were per-
formed using PASS 2002 (Hintze, J (2006) Kaysville, UT,
USA).
Data are presented as mean (SD) or n (%) for descrip-
tive purposes; however, measures of effect are presented
with the appropriate 95% CI. The primary analysis was a
comparison of the hyperuricemic response to a fructose
load in the entire group (n = 74), based on the presence
or absence of the 141 K gout risk allele. Secondary andring a fructose load in the entire group. (A) Serum urate
d as mean (95% CI). Sex and ancestry-adjusted graphs and P-values are
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excretion of uric acid following a fructose load in the en-
tire group, based on the presence or absence of the
141 K gout risk allele, and comparison of the hyperurice-
mic response to a fructose load based on subgroup ana-
lysis (within each ancestral subgroup).
Data were analyzed using a mixed models approach to
repeated measures. Significant main and interaction ef-
fects were explored using the method of Tukey. Where
indicated, sex and ancestry were adjusted for within the
models. For change in serum urate and other biochemical
variables, a mixed models analysis of covariance (ANCOVA)
approach to repeated measures was used. For ANCOVA,
the dependent variable was change from baseline, and
baseline level was included as a covariate. Differences in
participant characteristics between those with and without
the 141 K gout risk allele were analyzed using the t-test
for normally distributed data and Fisher’s exact test. All
analyses were performed using SAS (SAS Institute Inc
v 9.2). P <0.05 was considered significant and all tests were
two-tailed.Figure 2 The effect of ABCG2 genotype on serum glucose and fractio
entire group. (A) Serum glucose concentration. (B) Change in serum gluc
as mean (95% CI). Sex- and ancestr-adjusted graphs and P-values are showResults
Participant characteristics
The 141 K risk allele was present in 23 participants (31%).
There were 7 (9%) participants who were homozygous for
the risk allele and 16 (22%) who were heterozygous for the
risk allele. The baseline characteristics for those with and
without the 141 K gout risk allele are shown in Table 1.
There were more males in the group with the risk allele
(P = 0.023). In all subsequent analysis, sex was included as
a covariate in the mixed models analysis. The 141 K allele
was present in only 4/23 Eastern Polynesian participants,
and for this reason the Western and Eastern Polynesian
groups were pooled into a single Polynesian group for the
subsequent analysis. Unadjusted baseline serum urate
concentrations were higher in the group with the 141 K
allele. However, there was no difference in baseline serum
urate concentrations between groups after adjusting for
sex. Unadjusted baseline FEUA values did not differ bet-
ween the two groups, but after adjusting for sex, baseline
FEUA values were higher in the participants with the
141 K risk allele.nal excretion of uric acid (FEUA) during a fructose load in the
ose concentration. (C) FEUA. (D) Change in FEUA. Data are presented
n throughout. ANCOVA, analysis of covariance.
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during a fructose load in the entire group
Overall, serum urate concentrations during the fructose
load were similar in those with and without the 141 K
allele (PSNP = 0.15) (Figure 1A). However, the presence
of the 141 K allele was associated with a smaller increase
in serum urate following fructose intake (PSNP <0.0001)
(Figure 1B). This effect was observed after 60 minutes
and persisted throughout the study period. A similar re-
sult was observed in the change in serum urate when
only the male participants were included in the analysis
(n = 43, PSNP = 0.0001).
Separation of those with the risk allele into heterozygous
and homozygous for the risk allele showed that both
groups were associated with a similar smaller increase in
serum urate following fructose intake compared with the
group without the risk allele, but that there was no signifi-
cant difference in the urate response between the hetero-
zygous and homozygous groups (mixed models ANCOVA
sex- and ancestry-adjusted Pgenotype = 0.0003; post hocFigure 3 The effect of ABCG2 genotype on serum urate concentration
urate concentration. (B) Change in serum urate concentration. Unless state
graphs and P-values are shown throughout. Left panel shows European Ca
are presented as mean (95% CI). Sex-adjusted graphs and P-values are showtests none versus heterozygous for risk allele, P = 0.0006;
none versus homozygous for risk allele, P = 0.07; hetero-
zygous versus homozygous for risk allele, P = 0.95). Given
the lack of difference between the heterozygous and
homozygous risk allele groups and the small numbers of
participants who were homozygous for the risk allele, the
remaining analysis was done as presence versus absence
of the risk allele.
Those with the 141 K allele also had a lower serum glu-
cose and smaller increase in serum glucose following the
fructose load (PSNP = 0.002) (Figure 2A and 2B). Serum
lactate and fructose concentrations were not different
between those with and without the 141 K allele 60 minutes
after the fructose intake (sex- and ethnicity-adjusted
P = 0.91 and 0.21 respectively, Additional file 1: Figure S1).
Higher FEUA at baseline and throughout the fructose
load was observed in those with the 141 K allele
(PSNP <0.0001) (Figure 2C). However, the change in FEUA
in response to fructose was not different in those with and
without the 141 K allele (PSNP = 0.39) (Figure 2D).s during a fructose load in the ancestral subgroups. (A) Serum
d, data are presented as mean (95% CI). Sex- and ancestry-adjusted
ucasian subgroup, right panel shows Māori and Pacific subgroup. Data
n throughout. ANCOVA, analysis of covariance.
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during a fructose load in ancestral subgroups:
prespecified subgroup analysis
In both the European Caucasian and Polynesian ancestral
subgroups, serum urate concentrations during fructose
challenge were similar in those with and without the 141 K
allele (Figure 3A). The presence of the 141 K allele was
associated with a smaller increase in serum urate concen-
trations following a fructose challenge in the Polynesian
ancestral subgroup, with a similar trend in the European
Caucasian ancestral subgroup (Figure 3B).
The 141 K allele was associated with lower serum glu-
cose and smaller increase in serum glucose following a
fructose challenge in the Polynesian subgroup, but not
the European Caucasian subgroup (Figure 4). European
Caucasian participants with the 141 K allele had higher
fractional excretion of uric acid at baseline and following a
fructose challenge than European Caucasian participants
without the 141 K allele (Figure 5A). These associationsFigure 4 The effect of ABCG2 genotype on serum glucose during a fr
concentration. (B) Change in serum glucose concentration. Data are presen
subgroup, right panel shows Māori and Pacific subgroup. Data are presente
throughout. ANCOVA, analysis of covariance.were not significantly observed in the Polynesian ancestral
subgroup (Figure 5A). The change in FEUA in response to
fructose was not different in the two groups in either
ancestral subgroup (Figure 5B).
Additional subgroup analysis
There were 29 (39%) participants with hyperuricemia de-
fined as serum urate concentrations ≥0.42 mmol/L. There
was no difference in serum urate, FEUA or glucose re-
sponses to fructose between those with and without hy-
peruricemia (data not shown). In contrast, analysis
subgroups based on BMI did show differences. There were
44 (59%) participants with BMI ≥25 kg/m2. The differ-
ences in change in serum urate and glucose were observed
in those with BMI ≥25 kg/m2 (for urate, sex- and
ethnicity-adjusted PSNP = 0.003 and for glucose, sex- and
ethnicity-adjusted PSNP = 0.0006), but not in those with
BMI <25 kg/m2 (for urate, sex- and ethnicity-adjusted
PSNP = 0.12 and for glucose, sex- and ethnicity-adjusteductose load in the ancestral subgroups. (A) Serum glucose
ted as mean (95% CI). Left panel shows European Caucasian
d as mean (95% CI). Sex-adjusted graphs and P-values are shown
Figure 5 The effect of ABCG2 genotype on fractional excretion of uric acid (FEUA) during a fructose load in the ancestral subgroups.
(A) FEUA. (B) Change in FEUA. Data are presented as mean (95% CI). Left panel shows European Caucasian subgroup, right panel shows Māori
and Pacific subgroup. Data are presented as mean (95% CI). Sex-adjusted graphs and P-values are shown throughout. ANCOVA, analysis
of covariance.
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FEUA were observed in those with BMI ≥25 kg/m2 and
<25 kg/m2 (sex- and ethnicity-adjusted PSNP = 0.36 and
0.79 respectively).
Discussion
This study has highlighted the complex role of ABCG2
in regulation of serum urate concentrations. The ABCG2
141 K allele was associated with smaller increases in
serum urate following a fructose load. This would be
considered an unexpected response for a hyperuricemia/
gout risk allele, and differs to that observed with SLC2A9
where the presence of the protective allele is associated
with a smaller change in serum urate compared to those
without the protective allele [17].
In this study, the presence of the 141 K gout risk allele
was also associated with lower glucose responses to the
fructose load. The direction of change in serum glucose is
similar to the direction of serum urate response, sug-
gesting that the 141 K allele may influence both serumurate and glucose response to fructose. This could be re-
lated to an influence of Q141K on hepatic conversion of
fructose to glucose, estimated to occur at a rate up to 60%
depending on sex and health status [18]. The serum urate
and glucose responses may be dependent or independent
of each other. ABCG2 is not known to transport glucose
or fructose. Furthermore, the lack of differences observed
in serum lactate or serum fructose responses does not
support the possibility that ABCG2 affects fructose ab-
sorption or degradation. The mechanism of this obser-
vation is currently unexplained, but could relate to ATP
utilization by the ABCG2 alleles - the 141 K allele causes
instability in the nucleotide binding domain and reduced
protein expression [5]. Attempts to replicate this finding
are warranted, particularly as other variants potentially
influencing glucose metabolism have recently been asso-
ciated with hyperuricemia in a large genome-wide asso-
ciation analysis [7].
Our data provide further support for the concept that
the ABCG2 141 K allele does not increase hyperuricemia/
Dalbeth et al. Arthritis Research & Therapy 2014, 16:R34 Page 8 of 9
http://arthritis-research.com/content/16/1/R34gout risk through direct effects on renal tubular uric acid
transport. Consistent with the report by Ichida et al. in
which the 141 K risk allele was associated with increased
urinary urate excretion in the Japanese population [8], we
observed higher FEUA in participants with the risk allele
both at baseline and after fructose loading, and no differ-
ence in the change in FEUA between the two groups.
These results again contrast with our study of SLC2A9, in
which the presence of the protective SLC2A9 allele was
associated with higher FEUA responses following a fruc-
tose load [17]. As ABCG2 is widely expressed in many tis-
sues other than the renal tubule [4], it seems likely that
the effects of ABCG2 genetic variation on hyperuricemia
and gout risk act on other sites of urate metabolism or
clearance, most likely gastrointestinal [8]. It is possible
that various uric acid transporters may influence the func-
tion of other transporters such as ABCG2, resulting in net
increases or reductions in uric acid excretion. Larger stu-
dies are required to replicate the current results and also
explore such interactions between transporters.
This work has demonstrated population-specific diffe-
rences in the genotype-specific biochemical responses to
fructose. In this study, the 141 K allele effects on change
in serum urate and glucose were more pronounced in
the Māori and Pacific ancestral subgroup. This effect
may be in part related to the effects of BMI; as for
SLC2A9 [17], the effects of ABCG2 genotype on serum
urate response were primarily observed in people with
high BMI. However, the significantly increased FEUA as-
sociated with the 141 K allele in the European Caucasian
subgroup was not observed in the Māori and Pacific an-
cestral subgroup. Māori and Pacific people have high
rates of early onset, severe hyperuricemia and gout [19],
primarily due to reduced renal uric acid excretion
[20,21]. The ABCG2 FEUA results are consistent with
the previous SLC2A9 fructose challenge analysis, in
which the SLC2A9-specific FEUA responses to fructose
were observed in the European Caucasian subgroup, but
not in the Māori and Pacific ancestral subgroup [17].
Together, these data suggest that other factors (genetic
or non-genetic) may override the effects of genetic va-
riants common to European Caucasian and Polynesian
populations in renal uric acid handling in Polynesian
people. Identification of these effects will be important
to understand the basis of hyperuricemia in these high-
risk groups.
Conclusions
In contrast to the predicted responses for a hyperuricemia/
gout risk allele, the 141 K allele is associated with smaller
increases in serum urate and higher FEUA following a
fructose load. There are also population-specific differences
in the genotype-specific biochemical responses to fructose.
The results suggest that ABCG2 interacts with extra-renalmetabolic pathways in a complex manner to regulate
serum urate and gout risk.
Additional file
Additional file 1: Figure S1. The effect of ABCG2 genotype on serum
fructose and lactate concentrations 60 minutes following fructose load.
Data are presented as mean (SD).
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